ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Avanos Medical's annualized net income for the quarter that ended in Mar. 2026 was $20.4 Mil. Avanos Medical's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $780.2 Mil. Therefore, Avanos Medical's annualized ROE % for the quarter that ended in Mar. 2026 was 2.61%.
The historical rank and industry rank for Avanos Medical's ROE % or its related term are showing as below:
AVNS'
s ROE % Range Over the Past 10 Years
Min: -37.98 Med: -0.83 Max: 6.84
Current: -9.41
During the past 13 years, Avanos Medical's highest ROE % was 6.84%. The lowest was -37.98%. And the median was -0.83%.
AVNS's ROE % is ranked worse than 65.83% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs AVNS: -9.41
Avanos Medical (NYSE:AVNS) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Avanos Medical ROE % Related Terms
Avanos Medical ROE % Historical Data
* Premium members only.
The historical data trend for Avanos Medical's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Avanos Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avanos Medical ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avanos Medical's ROE % distribution charts can be found below:
* The bar in red indicates where Avanos Medical's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Avanos Medical (AVNS) has a ROE % of 2.61% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Avanos Medical and its competitors. According to the industry distribution chart, Avanos Medical ranks #526 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 65.8%.
Is Avanos Medical's ROE % too high?
Avanos Medical's current ROE % is 2.61%. The Medical Devices & Instruments industry median ROE % is 2.42. Avanos Medical's value of 2.61% is 7.9% above this industry median. Based on the distribution chart, Avanos Medical ranks #526 out of 799 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Avanos Medical has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avanos Medical's ROE % compare to IRMD and TNDM?
According to the Medical Devices & Instruments industry distribution chart, Avanos Medical ranks #526 out of 799 companies for ROE %. This places Avanos Medical in the lower half of its industry. The industry median ROE % is 2.42. Avanos Medical's value of 2.61% is 7.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avanos Medical's current ROE % of 2.61% is 7.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Avanos Medical and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avanos Medical's current ROE % is 2.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avanos Medical stock overvalued right now?
Based on GuruFocus' analysis, Avanos Medical (AVNS) is currently considered Modestly Overvalued. The stock's GF Value™ is $19.43, compared to a current price of $24.95 — trading 28.4% above its estimated fair value. The current ROE % is 2.61% and 7.9% above the Medical Devices & Instruments industry median of 2.42. Avanos Medical's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Avanos Medical (AVNS), the current ROE % is 2.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avanos Medical (AVNS) Overvalued in 2026?
Based on GuruFocus' analysis, Avanos Medical stock appears to be overvalued.
The current stock price of $24.95 is trading 28.4% above its estimated GF Value™ of $19.43.
GuruFocus considers Avanos Medical to be Modestly Overvalued.
Key valuation signals for AVNS:
ROE %: 2.61%
GF Value™: $19.43 vs. price of $24.95 (28.4% above fair value)
Industry Position: 7.9% above the Medical Devices & Instruments median (#526 of 799)
No single metric tells the full story. See the AVNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
62GF Score
Get the complete analysis for AVNS
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVNS has been successfully added to your 
